Glutaminase - A potential target for cancer treatment
- PMID: 38939098
- PMCID: PMC11204126
- DOI: 10.37796/2211-8039.1445
Glutaminase - A potential target for cancer treatment
Abstract
The overexpression of glutaminase is reported to influence cancer growth and metastasis through glutaminolysis. Upregulation of glutamine catabolism is recently recognized as a critical feature of cancer, and cancer cells are observed to reprogram glutamine metabolism to maintain its survival and proliferation. Special focus is given on the glutaminase isoform, GLS1 (kidney type glutaminase), as the other isoform GLS2 (Liver type glutaminase) acts as a tumour suppressor in some conditions. Glutaminolysis linked with autophagy, which is mediated via mTORC1, also serves as a promising target for cancer therapy. Glutamine also plays a vital role in maintaining redox homeostasis. Inhibition of glutaminase aggravates oxidative stress by reducing glutathione level, thus leading to apoptotic-mediated cell death in cancer cells Therefore, inhibiting the glutaminase activity using glutaminase inhibitors such as BPTES, DON, JHU-083, CB-839, compound 968, etc. may answer many intriguing questions behind the uncontrolled proliferation of cancer cells and serve as a prophylactic treatment for cancer. Earlier reports neither discuss nor provide perspectives on exact signaling gene or pathway. Hence, the present review highlights the plausible role of glutaminase in cancer and the current therapeutic approaches and clinical trials to target and inhibit glutaminase enzymes for better cancer treatment.
Keywords: Autophagy; Cancer; Glutaminase; Glutaminase inhibitor; Glutamine; Redox homeostasis.
© the Author(s).
Conflict of interest statement
Conflicts of interest: All the authors declare that there is no conflict of interest in the content of this article.
Figures
Similar articles
-
Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells.Oncotarget. 2014 Aug 15;5(15):6087-101. doi: 10.18632/oncotarget.2173. Oncotarget. 2014. PMID: 25026281 Free PMC article.
-
Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.Nephrol Dial Transplant. 2018 Aug 1;33(8):1343-1353. doi: 10.1093/ndt/gfx349. Nephrol Dial Transplant. 2018. PMID: 29420817 Free PMC article.
-
GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.Theranostics. 2021 Jun 26;11(16):7844-7868. doi: 10.7150/thno.58655. eCollection 2021. Theranostics. 2021. PMID: 34335968 Free PMC article.
-
The role of glutaminase in cancer.Histopathology. 2020 Mar;76(4):498-508. doi: 10.1111/his.14014. Epub 2020 Feb 18. Histopathology. 2020. PMID: 31596504 Review.
-
Glutaminases regulate glutathione and oxidative stress in cancer.Arch Toxicol. 2020 Aug;94(8):2603-2623. doi: 10.1007/s00204-020-02838-8. Epub 2020 Jul 18. Arch Toxicol. 2020. PMID: 32681190 Review.
Cited by
-
Altered metabolism in cancer: insights into energy pathways and therapeutic targets.Mol Cancer. 2024 Sep 18;23(1):203. doi: 10.1186/s12943-024-02119-3. Mol Cancer. 2024. PMID: 39294640 Free PMC article. Review.
References
-
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. - PubMed
-
- Tang L, Zeng J, Geng P, Fang C, Wang Y, Sun M, et al. Global metabolic profiling identifies a pivotal role of proline and hydroxyproline metabolism in supporting hypoxic response in hepatocellular carcinoma. Clin Cancer Res. 2018;24:474–84. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous